• Home
  • A phase I/II study of rovalpituzumab tesirine in delta-like 3-expressing advanced solid tumors.

A phase I/II study of rovalpituzumab tesirine in delta-like 3-expressing advanced solid tumors.

Author List
Mansfield AS, Hong DS, Hann CL, Farago AF, Beltran H, Waqar SN, Hendifar AE, Anthony LB, Taylor MH, Bryce AH, Tagawa ST, Lewis K, Niu J, Chung CH, Cleary JM, Rossi M, Ludwig C, Valenzuela R, Luo Y, Aggarwal R
Publication
NPJ precision oncology
Publication ID (Profile URL)
https://researcherprofiles.org/profile/219153519
Publication Year
2021
PubMed ID
34354225
Publication Title
Mansfield AS, Hong DS, Hann CL, Farago AF, Beltran H, Waqar SN, Hendifar AE, Anthony LB, Taylor MH, Bryce AH, Tagawa ST, Lewis K, Niu J, Chung CH, Cleary JM, Rossi M, Ludwig C, Valenzuela R, Luo Y, Aggarwal R. A phase I/II study of rovalpituzumab tesirine in delta-like 3-expressing advanced solid tumors. NPJ Precis Oncol. 2021 Aug 05; 5(1):74.
Publication Medline TA
NPJ Precis Oncol
Date
2021-08-05